<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327532</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01455-48</org_study_id>
    <nct_id>NCT03327532</nct_id>
  </id_info>
  <brief_title>Acute Heart Failure - COngestion Repeated Evaluation (AHF-CORE)</brief_title>
  <acronym>AHF-CORE</acronym>
  <official_title>Acute Heart Failure - COngestion Repeated Evaluation (AHF-CORE). Evaluation répétée de la Congestion au Cours d'Une Hospitalisation Pour Insuffisance Cardiaque aigüe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AHF-CORE study is a prospective, non-randomized, multicenter regional study.&#xD;
&#xD;
      The main objective of the AHF-CORE study is to identify congestion markers (clinical,&#xD;
      biological and ultrasound) at the beginning and at the end of hospitalization for acute heart&#xD;
      failure that are more strongly associated with the risk of all cause death or&#xD;
      rehospitalization for acute heart failure within 3 months of hospital discharge.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  Quantify the variations in congestion markers between the beginning and end of&#xD;
           hospitalization for acute heart failure.&#xD;
&#xD;
        -  Assess the correlation between changes in congestion markers between the beginning and&#xD;
           end of hospitalization.&#xD;
&#xD;
        -  Identify the congestion markers at the beginning of hospitalization that are most&#xD;
           strongly associated with residual congestion at the end of hospitalization.&#xD;
&#xD;
        -  Identify the added value of ultrasound and biological markers of congestion in addition&#xD;
           to clinical variables for the prediction of all-cause death or hospitalization for acute&#xD;
           heart failure at 3 months after hospital discharge.&#xD;
&#xD;
        -  Identify the association of ultrasound and biologic congestion markers assessed at&#xD;
           admission and final discharge with NYHA class at 3 months after hospital discharge&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congestion (clinical, biological and ultrasound evaluation) will be quantified at inclusion&#xD;
      within 72 hours of admission and before hospital discharge.&#xD;
&#xD;
      Follow-up at 3 months of hospital discharge will be performed through telephone interviews.&#xD;
      Vital status and rehospitalization status will be collected.&#xD;
&#xD;
      Throughout the study, patients will continue to be treated according to usual routine care,&#xD;
      regardless of their level of congestion. There will be no modification of treatment according&#xD;
      to the congestion data acquired within the setting of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>at 3 months after hospital discharge</time_frame>
    <description>composite criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rehospitalization for acute heart failure</measure>
    <time_frame>at 3 months after hospital discharge</time_frame>
    <description>composite criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical congestion markers as assessed with the Ambrosy Score</measure>
    <time_frame>at admission and at final discharge (an average of 10 days after admission)</time_frame>
    <description>Clinical congestion markers as assessed with the Ambrosy Score at admission and at final discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natriuretic peptides</measure>
    <time_frame>at admission and at final discharge (an average of 10 days after admission)</time_frame>
    <description>Natriuretic peptides at admission and at final discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated plasma volume</measure>
    <time_frame>at admission and at final discharge (an average of 10 days after admission)</time_frame>
    <description>Estimated plasma volume at admission and at final discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound congestion markers</measure>
    <time_frame>at admission and at final discharge (an average of 10 days after admission)</time_frame>
    <description>B lines, pleural effusion, E/e', DTE, TRV, VCI, Jugular diameter, renal venous blood flow pattern, peritoneal effusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual congestion</measure>
    <time_frame>at final discharge (an average of 10 days after admission)</time_frame>
    <description>as defined as an Ambrosy score 3 or more and/or B-lines score 30 or more and/or an IVC&gt;21 and IVC collapse with sniff &lt;50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>NYHA class (1, 2, 3, 4)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm study.&#xD;
Patients hospitalized for acute heart failure will undergo the following evaluations:&#xD;
Clinical examination centered on congestion&#xD;
Cardiopulmonary and peritoneal ultrasound&#xD;
Blood sample retrieved for biological assessment and biobanking&#xD;
Telephone interview</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clinical examination centered on congestion</intervention_name>
    <description>Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardio-pulmonary and peritoneal ultrasound</intervention_name>
    <description>Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample retrieved for biological assessment and biobanking</intervention_name>
    <description>Blood sample collection will be performed within 72 hours of admission and before discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone interview</intervention_name>
    <description>Telephone interview will be performed 3 months after discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urinary sample retrieved for biological assessment and biobanking</intervention_name>
    <description>Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients hospitalized for left-sided or global acute heart failure due to exacerbation&#xD;
             of chronic heart failure within 72 hours of admission to hospital&#xD;
&#xD;
          -  Patients over 60 years old&#xD;
&#xD;
          -  Person affiliated to or beneficiary of a social security plan&#xD;
&#xD;
          -  Person informed about study organization and having signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Comorbidity for which life expectancy is ≤ 3 months&#xD;
&#xD;
          -  Diagnosis of heart failure made less than 3 months prior to inclusion&#xD;
&#xD;
          -  Exacerbation of heart failure attributed to acute ischemic stroke (acute coronary&#xD;
             syndrome with or without ST segment elevation)&#xD;
&#xD;
          -  Dialyzed patient (peritoneal dialysis or hemodialysis) and patients with glomerular&#xD;
             filtration rate &lt;15 ml / min / m2 at baseline&#xD;
&#xD;
          -  History of pulmonary lobectomy or pneumonectomy&#xD;
&#xD;
          -  Severe pulmonary or pleural disease preventing the reliable acquisition of pulmonary&#xD;
             ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis&#xD;
&#xD;
          -  Suspected cardiac amylose or proven cardiac amylose&#xD;
&#xD;
          -  Exacerbation of heart failure attributed to valvular heart disease&#xD;
&#xD;
          -  Woman of childbearing age without effective contraception&#xD;
&#xD;
          -  Persons referred in articles L.1121-5, L.1121-7, L.1121-8 and L.1122-2 of the French&#xD;
             Public Health Code: Pregnant, parturient or breastfeeding woman ; Minor person&#xD;
             (non-emancipated) ; Adult person under legal protection (any form of public&#xD;
             guardianship) ; Adult person incapable of giving consent and not under legal&#xD;
             protection.&#xD;
&#xD;
          -  Persons deprived of liberty for judicial or administrative decision&#xD;
&#xD;
          -  Persons subject to psychiatric care under articles L.3212-1 and L.3213-1 of the French&#xD;
             Public Health Code&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas GIRERD, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation Clinique 1433 module Plurithématique de Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas GIRERD, MD,PhD</last_name>
    <phone>+ 33 3 83 15 74 96</phone>
    <phone_ext>+ 33 3</phone_ext>
    <email>n.girerd@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHR Metz-Thionville - Hôpital de Mercy</name>
      <address>
        <city>Metz</city>
        <state>Lorraine</state>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Noura ZANNAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy Hôpitaux de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Lorraine</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas GIRERD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 6, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Pr. Nicolas GIRERD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Heart Failure</keyword>
  <keyword>Congestion</keyword>
  <keyword>Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

